Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $590 - $605 million -- KPL-387 ...

Nektar Therapeutics’s NKTR share price has surged by 6.77%, which has investors questioning if this is right time to sell.

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

For one, microglia hovering around plaques—the type that express the most TREM2—reportedly become desensitized to stimulation ...

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to ...

Background Muscle wasting and weakness (sarcopenia) are commonly associated with COPD causing frailty and reduced quality of ...

DelveInsight's "ENTYVIO Market Size, Forecast, and Market Insight Report" highlights the details around ENTYVIO, a gut-selective ...

There is a strong correlation between soluble tumor necrosis factor receptors (sTNFR1 and sTNFR2) and cardiac and functional parameters in CCC, but their prognostic value remains unknown. OBJECTIVE To ...

Here, we identify formyl-peptide receptor type 2 (FPR2) as a therapeutic target to ... In human monocytes, the FPR1/2 agonist synergised with CCL2 to enhance chemotaxis and CCR2 signalling, unlike the ...

ICRAFT pinpointed TNFAIP3 (A20) as a crucial gene with dual immunoregulatory effects: In tumor cells, loss of TNFAIP3 activates TNF-induced apoptosis, upregulates NF-κB signaling, and enhances ...